This hypothesis is supported by the fact that pro-inflammatory cytokines (e.g. IL-1β, IL-6 and TNF-α) modulate the metabolism of these biomolecules; hence, dyslipidemia and hyperglycemia observed in the ICU-admitted patients could also be due to an inadequate cellular secretion of cytokines and/or an inappropriate immune response induced by SARS-CoV-2.68,69(b) Oxidative stress promoted by SARS-COV-2 infection could exacerbate dyslipidemia in COVID-19 patients with underlying metabolic disorders. This evidence concerns the gene IL1B and COVID-19.